Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131373 | 0.91 | ALDH1A1 (0.41) | SRCHSD11B1ALDH1A1MAPTESR2 | |
| SCHEMBL10255074 | 0.91 | ALDH1A1 (0.41) | SRCHSD11B1ALDH1A1MAPTESR2 | |
| SCHEMBL1068111 | 0.90 | HSD17B10 (0.43) | SRCALDH1A1SMN1; SMN2 | |
| SCHEMBL1068114 | 0.90 | HSD17B10 (0.43) | SRCALDH1A1SMN1; SMN2 | |
| SCHEMBL13898314 | 0.85 | MAPT (0.51) | HSD11B1ALDH1A1MAPTESR2UCHL1 | |
| SCHEMBL3892192 | 0.81 | ABL1 (0.37) | SRCPOLBSMN1; SMN2USP30 | |
| SCHEMBL1130985 | 0.81 | ALDH1A1 (0.42) | HSD11B1ALDH1A1MAPTESR2UCHL1 | |
| SCHEMBL10254762 | 0.79 | AGTR2 (0.42) | SRCUCHL1AGTR2HTRA1USP30 | |
| SCHEMBL29255152 | 0.79 | LTA4H (0.49) | — | |
| SCHEMBL2834188 | 0.74 | HPGDS (0.59) | SRCHSD11B1ALDH1A1MAPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155729-B1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-2155729-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-7501422-B2 | Prolinamide-tetrazole derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501422-B2 | Prolinamide-tetrazole derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080306089-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-11 | — | — | US | disclosed |
| WO-2008148688-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306089-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306089-A1 | PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, TAC3, NPSR1 | SRC 3420/4885HSD11B1 1975/4885ALDH1A1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.